A Agilent Technologies Inc.

Agilent Announces Thought Leader Award to Professor Christoph Herwig

(NYSE: A) today announced has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of bioprocess technology, Christoph Herwig is a Professor of Biochemical Engineering at , Vienna, Austria.

Prof. Herwig’s work focuses on developing end-to-end scientific workflows in bioprocess technology. His interdisciplinary approach aims to generate a holistic process control strategy, including LC/MS process analytical technology (PAT) solutions to determine critical quality attributes (CQAs) directly and in real time. His group also concentrates on establishing "digital twins" – data-rich virtual copies of physical processes – which, together with continuous PAT measurements, will enable real-time state estimation and auto-feedback control of the bioprocess.

Bioprocess digital twins are an exciting new technology that changes how researchers do bioprocess development, process validation, and cGMP operations. Digital twins organize bioprocess development, can suggest experimental designs, and manage new knowledge, which dramatically cuts process development costs and accelerate commercialization by combining previous platform knowledge to predict future process results. Smart, automated bioprocessing including digital twins is becoming an important topic within the fast-growing biopharmaceutical industry.

“I feel very honored to receive this prestigious award, and I thank Agilent for their innovative mindset of future bioprocess design! Moreover, I am certain that our collaboration in this interdisciplinary field of PAT and digital twins possesses disruptive potential to deliver high-quality, yet affordable, drugs for the world,” said Prof. Herwig.

“It is a great pleasure to grant Prof. Herwig this Agilent Thought Leader Award,” said Stefan Schuette, vice president and general manager of Agilent’s Liquid Phase Separations Division and executive sponsor of the award. “Collaborating with leading experts on advancing bioprocessing to the next, smart, and automated level is a great privilege. With this award, Agilent supports the development of important innovations to help the fast-growing biopharmaceutical industry develop new drugs faster and with higher quality.”

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the web site.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
12/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch